Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 3, 2014, Pages

  Pita, Jaime Miguel ^a,b   Figueiredo, Inês Filipa ^a,b   Moura, Margarida Maria ^a,b   Leite, Valeriano ^a,b   Cavaco, Branca Maria ^a,b  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; PROTEIN P53; RAS PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAF GENE; CARCINOGENESIS; CDKI GENE; CDKN3 GENE; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; CTNNB1 GENE; DIFFERENTIATED THYROID CANCER; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; ONCOGENE RAS; PIK3CA GENE; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; SNAI2 GENE; TP53 GENE; TUMOR DIFFERENTIATION; TUMOR GENE; UPREGULATION;

CELL CYCLE; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, RAS; HUMANS; MALE; MICROARRAY ANALYSIS; MUTATION; THYROID NEOPLASMS;

EID: 84895822573     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1512     Document Type: Article

References (59)

1. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16:17-44.
2. Wang HM, Huang YW, Huang JS, et al. Anaplastic carcinoma of the thyroid arising more often from follicular carcinoma than papillary carcinoma. Ann Surg Oncol. 2007;14:3011-3018.
3. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2008;93:278-284.
4. Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005;103:2261-2268. (Pubitemid 40686569)
5. Garcia-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. β-Catenin dysregulation in thyroid neoplasms: downregulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol. 2001;158:987-996. (Pubitemid 32221790)
6. Garcia-Rostan G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65:10199-10207. (Pubitemid 41743711)
7. Salvatore G, Nappi TC, Salerno P, et al. A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma. Cancer Res. 2007;67:10148-10158. (Pubitemid 350070786)
8. Montero-Conde C, Martin-Campos JM, Lerma E, et al. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene. 2008;27:1554-1561. (Pubitemid 351347876)
9. Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE. Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid. 2006;16:161-175.
10. Pita JM, Banito A, Cavaco BM, Leite V. Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas. Br J Cancer. 2009;101:1782-1791.
11. Kurihara T, Ikeda S, Ishizaki Y, et al. Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid. 2004;14:1020-1029. (Pubitemid 40076126)
12. DeLellis RA, Lloyd RV, Heitz PU, Eng C. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004: 50-80.
13. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4:249-264.
14. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA. 2001;98:31-36. (Pubitemid 32095858)
15. Khatri P, Draghici S, Ostermeier GC, Krawetz SA. Profiling gene expression using onto-express. Genomics. 2002;79:266-270.
16. Draghici S, Khatri P, Tarca AL, et al. Asystems biology approach for pathway level analysis. Genome Res. 2007;17:1537-1545. (Pubitemid 47529438)
17. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545-15550. (Pubitemid 41528093)
18. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet. 2006;38:500-501.
19. Nambiar A, Pv S, Susheelan V, Kuriakose MA. The concepts in poorly differentiated carcinoma of the thyroid: a review article. J Surg Oncol. 2011;103:818-821.
20. Lam KY, Lo CY, Chan KW, Wan KY. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg. 2000;231:329-338.
21. Volante M, Landolfi S, Chiusa L, et al. Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. Cancer. 2004;100:950-957. (Pubitemid 38222855)
22. Hébrant A, Dom G, Dewaele M, et al. mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switch. PLoS One. 2012;7:e37807.
23. Rodrigues RF, Roque L, Krug T, Leite V. Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines. Br J Cancer. 2007;96:1237-1245. (Pubitemid 46625062)
24. Onda M, Emi M, Yoshida A, et al. Comprehensive gene expression profiling of anaplastic thyroid cancers with cDNA microarray of 25 344 genes. Endocr Relat Cancer. 2004;11:843-854. (Pubitemid 40065556)
25. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17:548-558. (Pubitemid 41267170)
26. Wiseman SM, Masoudi H, Niblock P, et al. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg. 2006;191:581-587.
27. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, de la Chapelle A, Kloos RT. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2005;18:48-57. (Pubitemid 40128094)
28. Scheel C, Eaton Elinor N, Li Sophia H-J, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011;145:926-940.
29. Riesco-Eizaguirre G, Rodriguez I, De la Vieja A, et al. The BRAFV 600E oncogene induces transforming growth factor β secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res. 2009;69:8317-8325.
30. Vasko V, Espinosa AV, Scouten W, et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA. 2007;104:2803-2808. (Pubitemid 46327960)
31. Knauf JA, Sartor MA, Medvedovic M, et al. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene. 2011;30:3153-3162.
32. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415-428. (Pubitemid 46809165)
33. Moreno-Bueno G, Cubillo E, Sarrio D, et al. Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Res. 2006;66:9543-9556. (Pubitemid 44623653)
34. Wang Y, Ngo VN, Marani M, et al. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells. Oncogene. 2010;29:4658-4670.
35. Zhang Y, Yan W, Chen X. Mutant p53 disrupts MCF-10A cell polarity in three-dimensional culture via epithelial-to-mesenchymal transitions. J Biol Chem. 2011;286:16218-16228.
36. Garcia-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of β-catenin in anaplastic thyroid carcinoma. Cancer Res. 1999;59: 1811-1815. (Pubitemid 29186147)
37. Rocha AS, Soares P, Fonseca E, Cameselle-Teijeiro J, Oliveira MC, Sobrinho-Simões M. E-cadherin loss rather than β-catenin alterations is a common feature of poorly differentiated thyroid carcinomas. Histopathology. 2003;42:580-587. (Pubitemid 36688152)
38. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: cell cycle regulators and beyond. Dev Cell. 2008;14:159-169. (Pubitemid 351189186)
39. Calabrò V, Strazzullo M, La Mantia G, et al. Status and expression of the p16INK4 gene in human thyroid tumors and thyroid-tumor cell lines. Int J Cancer. 1996;67:29-34. (Pubitemid 26236065)
40. Boltze C, Zack S, Quednow C, Bettge S, Roessner A, Schneider-Stock R. Hypermethylation of the CDKN2/p16INK4A promoter in thyroid carcinogenesis. Pathol Res Pract. 2003;199:399-404. (Pubitemid 36974825)
41. Ball E, Bond J, Franc B, Demicco C, Wynford-Thomas D. An immunohistochemical study of p16(INK4a) expression in multistep thyroid tumourigenesis. Eur J Cancer. 2007;43:194-201. (Pubitemid 46054468)
42. Tung WS, Shevlin DW, Bartsch D, Norton JA, Wells SA Jr, Goodfellow PJ. Infrequent CDKN2 mutation in human differentiated thyroid cancers. Mol Carcinog. 1996;15:5-10. (Pubitemid 26072882)
43. Lee SW, Reimer CL, Fang L, Iruela-Arispe ML, Aaronson SA. Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Mol Cell Biol. 2000;20:1723-1732. (Pubitemid 30100191)
44. Yu Y, Jiang X, Schoch BS, Carroll RS, Black PM, Johnson MD. Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. Cancer Res. 2007;67:130-138. (Pubitemid 46142768)
45. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13:1161-1170. (Pubitemid 46424056)
46. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997;57:4710-4713. (Pubitemid 27468972)
47. Frisk T, Foukakis T, Dwight T, et al. Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes Cancer. 2002;35:74-80. (Pubitemid 34847871)
48. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003;88:5399-5404. (Pubitemid 37452745)
49. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch. 2004;444:572-576. (Pubitemid 38858382)
50. Volante M, Rapa I, Gandhi M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94:4735-4741.
51. Garcia-Rostan G, Zhao H, Camp RL, et al. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21:3226-3235. (Pubitemid 46606254)
52. Tsiatis AC, Norris-Kirby A, Rich RG, et al. Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications. J Mol Diagn. 2010;12:425-432.
53. Jancik S, Drabek J, Berkovcova J, et al. A comparison of direct sequencing, pyrosequencing, high resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas. J Exp Clin Cancer Res. 2012;31:79.
54. Querings S, Altmuller J, Ansen S, et al. Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One. 2011;6:e19601.
55. Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008;15:1069-1074.
56. Caillou B, Talbot M, Weyemi U, et al. Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One. 2011;6:e22567.
57. Selivanova G. Therapeutic targeting of p53 by small molecules. Semin Cancer Biol. 2010;20:46-56.
58. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol. 2011;137:1409-1418.
59. Meulmeester E, Ten Dijke P. The dynamic roles of TGF-β in cancer. J Pathol. 2011;223:205-218.